Response to Alpelisib in Clinically Distinct Pediatric Patients With PIK3CA-related Disorders.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of pediatric hematology/oncology"
DOI: 10.1097/mph.0000000000002418
Abstract: PIK3CA-related disorders include vascular malformations, potential overgrowth of various tissues, limb abnormalities, disordered soft tissue, and/or fatty hyperplasia that often leads to significant morbidity. Alpelisib, a targeted inhibitor of p110α, an enzyme encoded by the… read more here.
Keywords: patients pik3ca; pik3ca related; response alpelisib; clinically distinct ... See more keywords